North America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User

Description

List of Tables

The North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031; it is estimated to register a CAGR of 8.0% from 2023 to 2031.

Expanding Range of Application of Pharmacokinetic Studies Fuels North America Pharmacokinetics Services Market

Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.

North America Pharmacokinetics Services Market Overview

The US accounts for the largest share of the North America pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021.

North America Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

North America Pharmacokinetics Services Market Segmentation

The North America pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. The US dominated the North America pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the North America pharmacokinetics services market.

Product Code: BMIRE00030931

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Pharmacokinetics Services Market Landscape

4.1 PEST Analysis

5. North America Pharmacokinetics Services Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Chronic and Infectious Diseases
- 5.1.2 Expanding Range of Application of Pharmacokinetic Studies
- 5.1.3 Outsourcing of Pharmacokinetics Services to CROs
5.2 Market Restraints
- 5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.3 Market Opportunities
- 5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.4 Future Trend
- 5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.5 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - North America Analysis

6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

7. North America Pharmacokinetics Services Market Analysis - by Drug Type

7.1 Overview
7.2 Small Molecule
- 7.2.1 Overview
- 7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
- 7.3.1 Overview
- 7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
- 7.4.1 Overview
- 7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Pharmacokinetics Services Market Analysis - by Service Type

8.1 Overview
8.2 Pre-Clinical ADME and Human Studies
- 8.2.1 Overview
- 8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 PK/PD Analysis and Reporting
- 8.3.1 Overview
- 8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Dosing Simulations
- 8.4.1 Overview
- 8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Risk Analysis
- 8.5.1 Overview
- 8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application

9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
- 9.2.1 Overview
- 9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
- 9.3.1 Overview
- 9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
- 9.4.1 Overview
- 9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
- 9.5.1 Overview
- 9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
- 9.6.1 Overview
- 9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
- 9.7.1 Overview
- 9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.8 Others
- 9.8.1 Overview
- 9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Pharmacokinetics Services Market Analysis - by End User

10.1 Pharmaceutical and Biotechnology Companies
- 10.1.1 Overview
- 10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
- 10.2.1 Overview
- 10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Others
- 10.3.1 Overview
- 10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Pharmacokinetics Services Market - Country Analysis

11.1 North America
- 11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  - 11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.1.1 Overview
    - 11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
  - 11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.2.1 Overview
    - 11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
  - 11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.3.1 Overview
    - 11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

12.1 Charles River Laboratories International Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Eurofins Scientific SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Evotec SE
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Certara Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
12.5 Parexel International Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Allucent
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 PACIFIC BIOLABS
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 SGS SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms for Pharmacokinetic Services Market